Michael Choti, MD
Surgical Oncology · Dallas, TXNPI 1104878099
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 69.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $4,504 and has fallen 61.5% since, to $1,736 in 2025.
Across 12 payments — averaging $525.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- Histosonics, Inc.$2K
- Medtronic$115
- Davol Inc.$60
- Johnson & Johnson$24
- Merck$18
- plus $29 from 2 others
What the payments were for
- Consulting fees$3,16550%
- Travel & lodging$2,43739%
- Food & beverage$69011%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 4 | $4,389 |
| Histosonics, Inc. | 2 | $1,676 |
| Medtronic | 1 | $115 |
| Davol Inc. | 1 | $60 |
| Johnson & Johnson | 1 | $24 |
| Merck | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,311 in reported general payments places this provider in the 75th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Dallas
- Allison DipasqualeDallas$272K
- Adam YoppDallas$96K
- Peter BeitschDallas$62K
- Patricio PolancoDallas$61K
- William McNamaraDallas$16K
- Glen BalchDallas$11K
- Deborah FarrDallas$4K
- David KangDallas$4K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.